Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
53 hedge funds and large institutions have $15.8M invested in Marinus Pharmaceuticals, Inc in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 31 closing their positions.
1,792% more call options, than puts
Call options by funds: $227K | Put options by funds: $12K
29% less funds holding
Funds holding: 75 → 53 (-22)
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
71% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 31
78% less capital invested
Capital invested by funds: $72.9M → $15.8M (-$57.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$2.95M |
| 2 |
Morgan Stanley
New York
|
+$2.18M |
| 3 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
+$1.88M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$746K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$572K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$8.93M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$8.48M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$7.72M |
| 4 |
BL
Bleichroeder LP
New York
|
-$3.3M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.13M |
MRNS Hedge Fund Activity: Q4 2024 in Review
53 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2024, worth a combined $15.8M — down 78% from $72.9M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of MRNS and 9 opened new positions — a net loss of 22 holders — while 22 trimmed existing stakes and 13 added.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $2.95M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $8.93M sold.
- 53 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2024, down from 75 in Q3 2024.
- Funds reported $15.8M of Marinus Pharmaceuticals, Inc stock for Q4 2024, down 78% quarter-over-quarter.
- 9 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2024 and 31 closed out, a net change of -22 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2024 was Beryl Capital Management, an estimated $2.95M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2024 was Suvretta Capital Management, an estimated $8.93M sold.
Based on aggregated 13F filings for Q4 2024.